Vertex's Latest Finance Play: Selling Off EU Milestone Payments For Telaprevir
This article was originally published in The Pink Sheet Daily
Executive Summary
Curious announcement could presage a deal already in place or be an effort to draw competing bids.
You may also be interested in...
Vertex In The Vortex: More Cash, A Bigger Loss And The Departure Of A Key Executive
The drug maker sells future milestone payments for its Hepatitis C drug, but loses its chief commercial officer and head of strategic development.
Vertex In The Vortex: More Cash, A Bigger Loss And The Departure Of A Key Executive
The drug maker sells future milestone payments for its Hepatitis C drug, but loses its chief commercial officer and head of strategic development.
Telaprevir Simmering, Flush Vertex Raises $320 Million More
Firm moves away from “science-based” buyers and herds three institutional, longer-view backers into a single public offering.